Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
<< anterior 21 a 40 de 744 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014;384:2111-22. [Ref.ID 98453]
22. Cita con resumen
Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58. [Ref.ID 98362]
23.Tiene citas relacionadas Cita con resumen
Sibbing D, Massberg S. Dual antiplatelet treatment after stenting: is longer better?. Lancet 2014;384:1553-5. [Ref.ID 98305]
24.Tiene citas relacionadas Cita con resumen
Collet J-P, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G, for the ARCTIC Investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014;384:1577-85. [Ref.ID 98302]
25. Cita con resumen
Anónimo. Rivaroxaban 2,5 mg. Prescrire 2014;34:326-9. [Ref.ID 97554]
26. Cita con resumen
Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koening W, Jukema W, Nambi V, Wright S, Menon V, Lincoff M, Nissen SE, for the VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014;311:252-62. [Ref.ID 97043]
27.Tiene citas relacionadas Cita con resumen
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92. [Ref.ID 96671]
28.Tiene citas relacionadas
Mehta SR. Cangrelor: a new CHAMPION for percutaneous coronary intervention. Lancet 2013;382:1960-2. [Ref.ID 96669]
29.Tiene citas relacionadas
Mehta SR. Balancing thrombotic events and bleeding in primary PCI. N Engl J Med 2013;369:2263-5. [Ref.ID 96613]
30.Tiene citas relacionadas Cita con resumen
Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Berg JT, van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, for the EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17. [Ref.ID 96610]
31.Tiene citas relacionadas Cita con resumen
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Ioakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-22. [Ref.ID 96586]
32.Tiene citas relacionadas Cita con resumen
May AE. Antiplatelet therapy after coronary stenting: for how long?. Lancet 2013;382:1684-5. [Ref.ID 96584]
34. Cita con resumen
Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review.. JAMA 2013;310:189-98. [Ref.ID 96243]
35.Tiene citas relacionadas
Windecker S, Bax JJ, Mayt A, Stone GW, Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet 2013;382:644-57. [Ref.ID 96028]
36.Tiene citas relacionadas
Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?. Lancet 2013;382:633-43. [Ref.ID 96027]
37.Tiene citas relacionadas
Gershlick AH, Banning AP, Myat A, Verheugt FWA, Gersh BJ. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?. Lancet 2013;382:624-32. [Ref.ID 96026]
38.Tiene citas relacionadas
Bhatt DL, Harrington RA, for the CHAMPION PHOENIX Executive Committee and Investigators. Platelet inhibition with cangrelor during PCI. The authors reply. N Engl J Med 2013;369:393-4. [Ref.ID 95884]
39.Tiene citas relacionadas
Wong BYL. Platelet inhibition with cangrelor during PCI. N Engl J Med 2013;369:393. [Ref.ID 95883]
40.Tiene citas relacionadas
Dewilde WJM, Verheugt FWA, ten Berg JM. Antiplatelet therapy and anticoagulants - Authors' reply. Lancet 2013;382:25. [Ref.ID 95787]
Seleccionar todas
 
<< anterior 21 a 40 de 744 siguiente >>